Transforming cancer treatment through empowered science

Seattle Genetics was founded in 1998, and since 2001 the company’s stock has been publicly traded on Nasdaq under the symbol SGEN. Our leadership in antibody-drug conjugates (ADCs) and focus on innovative, targeted therapies for cancer, has resulted in one approved drug and a robust pipeline of programs in clinical development for lymphoma, leukemia, urothelial (bladder) and breast cancer.

Recent News

  • Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma MORE
  • Seattle Genetics Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A) in Frontline Acute Myeloid Leukemia MORE
  • Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed Hodgkin Lymphoma at the International Conference on Malignant Lymphoma  MORE

VIEW ALL NEWS

$63.25

 0.22 (0.35%)

06/22/17  4:00 p.m. ET

NASDAQ | SGEN (Common Stock)

High$64.80
Volume1,411,123
Low$63.00
Mkt Cap$9,026,824,760

Data provided by Nasdaq. Minimum 15 minutes delay

Seattle Genetics Fast Facts

NASDAQSGEN

Common Stock CUSIP812578 102

Fiscal Year Jan. 1 - Dec. 31

State IncorporatedDelaware

STAY CONNECTED

Investor Contact

Peggy Pinkston
Vice President, Investor Relations
investors@seagen.com
425-527-4160

Email Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site.

Get email alerts